PAR1 Inhibitors (Vorapaxar) Medmovie MOD/MOA Sample Only

(1:58)

How PARP inhibitors (PARPi) work

(3:12)

Atherothrombosis

(51:53)

\

(51:58)

Use of PARP1-selective and ATR inhibitors to target DDR signalling pathway

(58)

Vorapaxar thrombin receptor antagonist

(3:16)

PARP Inhibitors: Which One Should We Use?

(9:17)

What is a PARP Inhibitor?

(2:37)

Medical vocabulary: What does Receptor, PAR-1 mean

(21)

Dr. Litton on the Impact of PARP Inhibitors in Breast Cancer

(1:27)

Understanding the Biological Targets of PARP Inhibitors

(7:25)

PARP inhibitors – a cancer drug discovery story | Professor Ruth Plummer FMedSci

(12:11)

PAR4 inhibition as a novel therapeutic for multiple pathophysiologies

(1:31)

PARP Inhibitors for BRCA-Associated TNBC

(5:19)

Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical Oncologist

(58:46)

Development of Synthetic Aptamers for Use as Low Cost PLD1 Inhibitors

(15:45)

PARP Inhibitors in Recurrent Ovarian Cancer

(6:20)

Development and clinical indications of PARP inhibitors

(3:20)

A variety of approaches to measure the efficacy of PARP inhibitors

(4:41)